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Abstract
Neuroendocrine breast cancer lacks specific therapy, but similar common neuroendocrine carcinomas may
offer guidance for therapy development. This study, for the first time, identified several biomarkers for targeted
therapy approaches in patients with breast neuroendocrine carcinoma.
Introduction: Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly
constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several
new targeted therapies based on specific biomarkers were recently investigated in the NEC of lung and in other types
of breast carcinoma, which may provide guidance to their feasibility in breast NEC. Materials and Methods: Twenty
breast NECs were profiled for biomarkers of therapy including antibody-drug conjugates (DLL3, TROP-2, and FOLR1),
histone deacetylase (H3K36Me3) inhibitors, tropomyosin receptor kinases (NTRK1/2/3 gene fusions) targeted
inhibitors, alkylating agents (MGMT), and immune checkpoint inhibitors (PD-L1, TMB, and MSI) using immunohisto-
chemistry and DNA/RNA next-generation sequencing assays. Results: Predictive expression of TROP-2, FOLR1, and
H3K36Me3 were detected in different subsets of tumors and may pave the way for development of novel targeted
therapies in some patients with breast NECs. There was no evidence of DLL3 expression, NTRK gene fusions, or
MGMT hypermethylation. No biomarkers predictive of immune checkpoint inhibitor efficacy (programmed
death-ligand 1 expression, tumor mutational burden, microsatellite instability) were identified. FGFR and CCND1 gene
amplifications were detected in isolated cases. Conclusions: This study identified several potential targets for novel
therapies in breast NEC, including farletuzumab and mirvetuximab soravtansine (FOLR1), sacituzumab govitecan
(TROP-2), and HDAC inhibitors (H3K36Me3). In some cases, CCND1 gene amplification may indicate the usefulness of
investigational therapies. The reported results should serve as an early indication of potential clinical relevance in
selected patients with breast NEC.
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Breast neuroendocrine carcinoma (NEC) is a rare, special type of
cancer, reportedly constituting 2% to 5% of all breast cancers.1
Breast NECs are typically positive for estrogen (ER) and1College of Medicine, Qatar University, Doha, Qatar
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https://doi.org/10.1016/j.clbc.2018.09.001progesterone (PR) receptors and negative for ERBB2 (human
epidermal growth factor receptor 2 [Her-2]/neu).2-4 Despite its
luminal (A or B) phenotype,4,5 most studies have reported an
aggressive clinical course and poor outcome for patients with
NEC.2,4,6,7
The mutational profile and molecular characteristics of breast
NEC have been the focus of several recent studies.3,4,8,9 In contrast
to gastroenterohepatic NECs,10 these studies revealed inconsistent
mutational profiles of NEC with limited targetable options (eg,
PIK3CA mutations in 7%-33% of the cases). The role of
programmed death-ligand 1 (PD-L1) as a predictor of the response
to immune checkpoint inhibitors was explored in 2 studies
involving only 6 cases of NEC.3,11 No systematic attempt to analyze
breast NECs for biomarkers of therapy used in NECs of otherClinical Breast Cancer Month 2018 - 1
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Novel Targets in Neuroendocrine Carcinoma of the Breastprimary sites (eg, DLL3 in lung)12 or different types of breast
carcinomas (eg, TROP-2, Folate Receptor 1, NTRK gene fusions)
has been published.13-15 Thus, we investigated this topic in a cohort
of invasive breast NECs.
Materials and Methods
Patients and Samples
The study included 20 surgical tumor samples previously defined
by strict criteria for the diagnosis of breast NEC (> 50% of the
neoplastic cells expressing neuroendocrine markers synaptophysin
and/or chromogranin-A).1,16 Board-certified pathologists (Z.G.,
J.P., S.S., and S.V.) reviewed all cases to confirm the diagnoses and
to select appropriate slides for molecular assays. None of the patients
had a history or concurrent NEC of the lung or any other extra-
mammary neuroendocrine neoplasm.
Immunohistochemistry
Immunohistochemical methods (IHC) were used to analyze
the expression of PD-L1, delta like canonical Notch ligand 3
(DLL3), folate receptor 1 (FOLR1), trimethylated Lys-36 of
histone 3 (H3K36me3), TROP-2 (or tumor-associated calcium
signal transducer 2 [TACSTD2]), and neurotrophic receptor
kinases 1-3 (pan-NTRK). O-6-Methylguanine-DNA Methyl-
transferase (MGMT) protein expression was evaluated using
IHC, whereas MGMT promoter methylation was analyzed by
pyrosequencing (manufacturers, clones, thresholds, and subcel-
lular localization for each biomarker are provided in Table 1). For
all IHC assays, both positive and negative controls reacted
appropriately. IHC assays were performed using fully automated
staining platforms (Ventana-Roche and DAKO-Agilent) in a
CLIA/CAP/ISO15189-certified clinical laboratory (Caris Life
Sciences, Phoenix, AZ).
Next-generation Sequencing (NGS)
The NGS panel included complete exon sequencing of 592 genes
(the full list of genes is available at: http://www.
carismolecularintelligence.com/solid_tumors_international). Tu-
mor mutational burden (TMB) was calculated using non-
synonymous missense mutations; common germline variants were
filtered from the analysis. High TMB was reported when  17
mutations/megabase were present (more info is available here:
https://www.carismolecularintelligence.com/wp-content/uploads/
2016/12/TN0291-v1_Total-Mutational-Load-Immunotherapy-Table 1 Overview of the Antibodies Used in the Study
Antibody Clone/Manufacturer Thres
DLL3 SP347 clone, Ventana
 5
TROP-2 Anti-human Trop-2, R&D Systems 
> 5
FOLR1 Clone 26B3.F2, Biocare Medical H-scor
H3K36me3 Rabbit polyclonal, Abcam
Pan-TRK Clone EPR17341, Abcam 
MGMT Monoclonal antibody MT 23.2, Invitrogen > 3
PD-L1 SP142, Ventana  5% t
nical Breast Cancer Month 2018REVERSED-PAGES.pdf). Microsatellite instability (MSI) status
was evaluated by analysis of microsatellite loci in the target regions
of the sequenced genes. High MSI was defined as  46 altered loci,
as previously reported.17-19
Gene copy number variations were identified by comparing the
depth of NGS sequence reads to reads from a diploid control. Genes
with  6 copies were considered amplified.17,18
ArcherDx FusionPlex Assay (ArcherDX, Boulder, CO) was used
to explore gene fusions. Fifty-three gene targets were analyzed in 12





The study included 19 naive primary and 1 metastatic (axillary
lymph node) patients with breast NEC. None of the patients had
been treated by chemotherapy, endocrine therapy, or radiotherapy
prior to the tumor sample collection. All the patients were women;
the mean age was 60 years (range, 43-83 years). The study included
4 grade 1 NEC, 11 moderately differentiated (grade 2), and 5
poorly differentiated (grade 3) NECs.
ER was positive in all 20 cases (100%), whereas PR was
expressed in 17 (85%) of 20 cases. ERBB2 was positive (over-
expressed and amplified) in 1 (5%) (ER-positive [ERþ],
PR-negative [PR]) case. Androgen receptor (AR) was positive (
10% positive cells) in 9 (50%) of 18 tested cases. Each breast
NEC stained diffusely and strongly for at least 1 neuroendocrine
biomarker: chromogranin-A (17þ of 20) and synaptophysin (19þ
of 20). These results are in line with previous data that revealed
the luminal A/B (ERþ) phenotype of the vast majority of
NECs.4,9,20 Given the positivity for ER and/or PR, most patients
with NEC are eligible for endocrine therapy against ER. AR
expression has been extensively studied in breast cancer, as a
diagnostic (eg, apocrine breast cancer),21 prognostic (favorable in
ERþ/AR-positive [ARþ] breast cancers),22 and predictive
biomarker (eg, clinical trials with antiandrogens in patients with
advanced/metastatic triple-negative breast cancer).23 AR expres-
sion has been previously described in NEC of the breast and
correlated with the expression of gross cystic disease fluid protein
expression.16 Information on the potential benefits of
antiandrogens in patients with NEC of the breast is not currently







e  1 ( 20 for high) Membranous
Any positivity Nuclear
1% of tumor cells Membranous/cytoplasmic and nuclear
5%,  1þ intensity Nuclear
umor cells, 2þ intensity Membranous/cytoplasmic
Table 2 The Status of Novel Predictive Biomarkers for Several Classes of Drugs
Biomarker Class/Name Function Mechanism of Action Targeted Drug Common Cancers Diagnostic Assay Status in NEC
Drug conjugates












IHC 1/19 high (> 50% cellsþ)
3/19 low (10%-30%) cellsþ
15/19 negative (0 < 10% cellsþ)
Folate receptor 1 (FOLR1) Folate antimetabolites
(eg, pemetrexed therapy)
[ Imaging probes, drug
conjugates, farletuzumab,
mirvetuximab




H3K36me3 (SETD2) Histone H3 lysine 36
methyltransferase






IHC and NGS Loss: 6/19 (32%)





and growth (activation by
neurotrophins)





IHC and Archer Fusion
assay (NGS)
18/19 (95%) negative






Y owing to promoter
methylation
Temozolomide GBM IHC and Pyro-sequencing None methylated (n ¼ 12)
Abbreviations: Ca ¼ calcium; CRC ¼ colorectal cancer; GMB ¼ glioblastoma multiforme; IHC ¼ immunohistochemistry; MASC ¼ mammary analogue secretory carcinoma; NEC ¼ neuroendocrine carcinoma; NGS ¼ next-generation sequencing; NSCLC ¼ nonesmall-cell lung
cancer; RCC ¼ renal cell carcinoma; SCLC ¼ small-cell lung cancer; TNBC ¼ triple-negative breast cancer.
[Denotes activation (overexpression).









Table 3 Genetic Alterations in Neuroendocrine Carcinoma of
the Breast
Genetic Alterations
(Number of Tested Cases)
Affected Genes in Neuroendocrine
Carcinomas
Mutations (n ¼ 12) TP53 (n ¼ 2)a
SETD2 (n ¼ 2) (one VUS)
PIK3CA, RB1, BRCA1 (VUS), IDH1,
ARID1A, MUTYH (n ¼ 1)
Fusions (n ¼ 10) None
Copy number variations
(n ¼ 12)
FGF3, FGF4 (n ¼ 3)
FGFR1, FGF19, CCND1, ZNF703,
WHSC1L1 (n ¼ 2)
FGF1, CDX2, MDM2, HMGA2,
SPECC1, GPR124 (n ¼ 1)
Abbreviation: VUS ¼ variant of unknown significance.
aNumbers in parenthesis represent number of cases with a certain gene alteration.
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Antibody-drug Conjugate (ADC) Targets. The targeted delivery of
drug conjugated to an antibody is a novel approach in cancer
treatment that has resulted in several recently approved therapies.24
The antibody component of the ADC is directed against an epitope
enriched in the targeted cancer cell population. The number of
ADCs is increasing rapidly; a recent study of Moek et al, based on a
comprehensive search of PubMed and ClinicalTrials.gov, revealed
87 ADCs directed against 59 unique targets.24 The authors applied
a functional genomic mRNA-profiling assay to predict the
frequency of protein predictive biomarkers to ADC targets across
various cancers. Their study revealed that ADC targets are
commonly expressed in cancers such as breast (especially in triple-
negative), lung, and prostate cancers.24 In our study, we chose to
investigate expression of 3 such epitopes that have shown promising
predictive values in either breast cancer or extramammary neuro-
endocrine neoplasms: DLL3, FOLR1, and TROP-2.
Low DLL3 expression was observed in 2 (11%) of 19 cases (5%
and 20% with weak 1þ positive cells, respectively) (Table 2). High
DLL3 expression (> 50% of cells) had been shown to predict
therapeutic benefit from rovalpituzumab tesirine (a DLL3-targeted
antibody-drug conjugate), in small-cell lung cancers,12 but none
of the tested breast NECs exhibited high DLL3 expression. Given
these results, it is unlikely that patients with breast NEC will benefit
from rovalpituzumab tesirine.
FOLR1 expression was detected in 6 (31.5%) of 19 cases, with
H-score  20 in 4 cases. FOLR1 expression in breast is predomi-
nantly observed in triple-negative breast cancers.13,25 High FOLR1
expression in nonesmall-cell lung cancer has been associated with a
more favorable outcome and a better response to pemetrexed
therapy.26 A number of FOLR-targeted agents have been developed,
including monoclonal antibodies and ADCs.27,28 A recent study by
Kalli et al indicates that FOLR vaccine may enhance the immune
response in patients with breast and ovarian cancers that overexpress
FOLR.29
TROP-2 protein expression was detected in 4 (21%) of 19 cases,
with 1 case exhibiting high (2þ / > 50% cells) Trop-2 expression.
TROP-2 is a cell-surface receptor that is over-expressed in various
carcinomas.14 It is a biomarker for sacituzumab govitecan, an
antibody-drug conjugate.14,30 In this ADC, the anti-Trop-2nical Breast Cancer Month 2018antibody (hRS7) serves as a mode of delivery for SN-38, the
active metabolite of irinotecan, an inhibitor of topoisomerase-1.14,30
Of note, topoisomerase-1 overexpression has been previously
reported in approximately 40% of breast NECs.3 In addition, a
recent phase II trial showed durable therapeutic responses induced
by sacituzumab govitecan in patients with heavily pretreated and
metastatic triple-negative breast cancers.31 Our results also suggest
that a small proportion of breast NECs may be amenable to treat-
ment with sacituzumab govitecan.
NTRK and Histone Deacetylase (HDAC) Inhibitors. NTRK
expression using pan-TRK antibody was negative in all but 1 case
that exhibited low (5%) positivity. NTRK gene fusions were absent
in all cases (Tables 2 and 3). Based on these findings as well as the
lack of ALK and ROS1 gene alterations, patients with breast NEC
are unlikely to benefit from the NTRK inhibitors (eg, larotrectinib
[or LOXO-101] and entrectinib [pan-Trk, ROS1, and ALK in-
hibitor]) in contrast to secretory breast carcinoma, characterized by
consistent ETV6-NTRK3 fusions and NTRK expression.15
Significantly, a complete loss of H3K36me3 was seen in 6 (32%)
of 19 cases. One of the cases with loss also harbored a loss of
function SETD2 gene mutation by NGS, whereas another had a
SETD2 variant of unknown significance. SETD2 is responsible for
H3K36me3 histone modification. Loss of function mutations in the
SETD2 gene are associated with impaired DNA methylation and
increased genomic instability. These genetic alterations have been
well-characterized in renal cell carcinoma32,33 and may be targeted
by HDAC inhibitors.34 SETD2-dependent histone H3K36 trime-
thylation is also essential for homologous recombination and
mismatch repair and has been implicated in resistance to DNA
damaging agents.35-37 Recent studies, however, have suggested that
H3K36me3-deficient cancers are sensitive to WEE1 inhibition38;




None of the tested cases of NEC (n ¼ 14) exhibited a loss of
MGMT protein by IHC, and the pyrosequencing assay detected no
MGMT promoter hypermethylation (n ¼ 10). These results indi-
cate a lack of benefit for patients with NEC from temozolomide, an
alkylating agent used for treatment of high-grade gliomas (eg,
glioblastoma multiforme) and melanomas with an epigenetically
silenced MGMT gene. A recent study by Gay et al reported a
therapeutic success and durable remission induced by temozolamide
in a patient with metastatic small-cell lung cancer39; a study from
Kulke et al also demonstrated sensitivity to temozolamide-based
therapy in > 30% pancreatic neuroendocrine tumors.40
Biomarkers of Response to Immune Checkpoint Inhibitors
PD-L1 expression in cancer cells (above 5% tumor cells’
threshold) was not observed in any case (n ¼ 19). Additionally, all
successfully tested cases (n ¼ 10) were microsatellite stable and
exhibited low TMB (5 mutations/Mb; range, 1-9 mutations).
These results are in line with previous studies on luminal breast
cancer that confirmed a low frequency (< 5%) or a complete lack
Semir Vranic et alof MSI and/or low TMB.41 Our data indicate that patients with
breast NEC would be ineligible for treatment with the current
immune checkpoint inhibitors (anti-programmed cell death
protein 1 [PD-1]/PD-L1 drugs) in contrast to patients with
PDeL1-positive metaplastic breast cancers and breast cancers with
high MSI or high TMB.42-44
NGS and Archer Fusion Results
NGS detected amplifications of genes in the fibroblast growth factor
signaling pathway (FGFR1, FGF3, FGF4, FGF19) and cyclin D1
(CCND1) (Table 3). The CCND1, FGF3, FGF4, and FGF19 genes
are localized together on chromosome 11 and often co-amplify.45
Pathogenic mutations were rare and affected TP53, SETD2,
PIK3CA, IDH1, and RB1 (Table 3). Gene fusions were not observed
in any of the tested cases (n ¼ 10). Observed genomic alterations of
NECs in our series are comparable with the data from previous studies
on NEC.4,8,9,46,47 The molecular alterations (PIK3CA, TP53, RB1,
CCND1) in breast NEC are common in invasive ERþ (luminal)
ductal carcinomas of no-special-type suggesting potential relevance of
cell cycle (CDK4/6 inhibitors) in isolated cases of this rare cancer.48,49
There are also ongoing clinical trials with cell cycle inhibitors aimed to
treat patients with lung and head/neck cancers harboring CCND1
amplification (trials: NCT03356223 and NCT02785939). Although
FGFR inhibitors have been recently considered as a promising thera-
peutic option in breast cancer, the preliminary clinical data with FGFR
inhibitors have yielded disappointing results.50 IDH1 (isocitrate de-
hydrogenase 1) mutations have also been described in breast cancer,
including luminal breast cancers,47 and have been associated with a
poor prognosis.51
Conclusions
This study for the first time identified several potential targets
for novel therapy approaches in breast NEC. Predictive expression
levels of FOLR1 and TROP-2 were detected in different, but small
subpopulations of patients with breast NEC. Additional biomarker
support (H3K36me3/SETD2) for the use of HDAC inhibitors
may be explored in selected breast NECs. Gene alterations seen in
common breast carcinomas, including those in the cell cycle
control pathway, were also found in breast NEC, suggesting
relevance of CDK4/6 inhibitors in isolated cases of this rare can-
cer. Patients with breast NEC are generally unlikely to benefit
from immune checkpoint inhibitors, as all current biomarkers
(PD-L1 expression, TMB, and MSI) are uniformly negative.
Reported results should serve as an early indication of potential
clinical relevance in selected patients with breast NEC (eg,
including patients with NEC in basket trials like the NCI-
MATCH trial [The National Cancer Institute-Molecular Analysis
for Therapy Choice] and other precision medicine trials that may
include rare cancers such as NEC of the breast).
Clinical Practice Points
 Predictive protein expression levels of FOLR1, TROP-2. and
H3K36Me3 were detected in single individuals or small sub-
populations of breast NEC samples.
 Gene alterations affecting cell-cycle control pathway suggest
relevance of cell-cycle (CDK4/6) inhibitors in isolated cases. The patients with breast NECs are unlikely to benefit from
immune checkpoint inhibitors as all currently approved bio-
markers (PD-L1 expression, TMB, and MSI) are uniformly
negative.Disclosure
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